Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...

The company also exhibited significant progress in its regulatory approvals, receiving 14 out of 22 MDR CE Marks, and expects approval for Artegraft, its largest American product, in Europe by June ...

鉴于此，公司已开始寻找新的CFO。 LeMaitre Vascular在监管方面取得重大进展，已获得22个MDR CE认证中的14个。公司预计其最大的美国产品Artegraft将在2025年6月前在欧洲获得批准。尽管由于制造效率和成本上升可能导致第三季度毛利率略有下降，但公司对其增长战略仍 ...